Rossella Menghini Selected Research

Tissue Inhibitor of Metalloproteinase-3

1/2017	Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
1/2016	A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction.
10/2015	TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice.
1/2012	Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice.
12/2011	Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness.
10/2009	TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.
2/2009	Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice.
12/2005	Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rossella Menghini Research Topics

Disease

13	Inflammation (Inflammations) 01/2022 - 04/2005
13	Atherosclerosis 01/2020 - 10/2009
10	Insulin Resistance 01/2022 - 02/2006
7	Obesity 01/2022 - 10/2007
5	Hyperglycemia 05/2021 - 07/2002
5	Type 2 Diabetes Mellitus (MODY) 03/2019 - 10/2009
4	Diabetic Nephropathies (Diabetic Nephropathy) 12/2021 - 12/2013
3	Fatty Liver 01/2022 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2004
3	Atherosclerotic Plaque (Atheroma) 12/2013 - 10/2009
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 12/2007
2	Hypertension (High Blood Pressure) 11/2021 - 10/2015
2	Fibrosis (Cirrhosis) 05/2021 - 01/2021
2	Dysbiosis 01/2020 - 01/2016
2	Neoplasms (Cancer) 12/2019 - 01/2017
2	Myocardial Infarction 10/2015 - 04/2015
2	Genetic Predisposition to Disease (Genetic Predisposition) 02/2009 - 01/2004
2	Glucose Intolerance 10/2007 - 12/2005
1	Non-alcoholic Fatty Liver Disease 01/2022
1	COVID-19 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Weight Gain 12/2021
1	Carotid Artery Diseases 11/2021
1	Renal Insufficiency (Renal Failure) 11/2021
1	Diabetes Mellitus 11/2021
1	Proteinuria 05/2021
1	Hypertrophy 01/2021
1	Albuminuria 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 02/2018
1	Overweight 03/2017
1	Carcinogenesis 01/2017
1	Liver Neoplasms (Liver Cancer) 01/2017
1	Heart Failure 01/2016
1	Ischemia 01/2016
1	Cicatrix (Scar) 10/2015

Drug/Important Bio-Agent (IBA)

10	Insulin (Novolin)FDA Link 02/2018 - 07/2002
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2011
8	Tissue Inhibitor of Metalloproteinase-3IBA 01/2017 - 12/2005
7	Glucose (Dextrose)FDA LinkGeneric 03/2019 - 07/2003
4	MicroRNAs (MicroRNA)IBA 12/2021 - 12/2013
4	Biomarkers (Surrogate Marker)IBA 05/2021 - 12/2013
4	Peptide Hydrolases (Proteases)FDA Link 12/2019 - 02/2012
4	DisintegrinsIBA 01/2017 - 10/2009
4	Insulin ReceptorIBA 12/2011 - 07/2003
4	ADAM17 ProteinIBA 01/2010 - 12/2005
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
3	EnzymesIBA 01/2022 - 09/2015
3	LipidsIBA 08/2021 - 02/2012
3	CollagenIBA 05/2021 - 01/2012
3	Tissue Inhibitor of MetalloproteinasesIBA 12/2019 - 02/2012
3	Metalloproteases (Metalloproteinases)IBA 01/2017 - 10/2009
3	Matrix Metalloproteinases (MMPs)IBA 10/2009 - 12/2005
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022 - 02/2014
2	Biological ProductsIBA 11/2021 - 12/2019
2	InterleukinsIBA 10/2021 - 06/2014
2	Streptozocin (Streptozotocin)FDA Link 01/2021 - 02/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2016
2	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 12/2019 - 01/2017
2	Apolipoproteins E (ApoE)IBA 10/2015 - 08/2014
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2007 - 12/2005
2	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 02/2006 - 07/2002
1	Arachidonic Acid (Vitamin F)IBA 01/2022
1	Phospholipases A2 (Phospholipase A2)IBA 01/2022
1	superoxide dismutase 2IBA 01/2022
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022
1	AntioxidantsIBA 01/2022
1	Angiotensin-Converting Enzyme 2IBA 01/2022
1	Branched-Chain Amino AcidsIBA 01/2022
1	Ligases (Synthetase)IBA 01/2022
1	UbiquitinIBA 01/2022
1	Long Noncoding RNAIBA 12/2021
1	TRAM 34IBA 12/2021
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 12/2021
1	Untranslated RNA (Noncoding RNA)IBA 12/2021
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 12/2021
1	oxidized low density lipoproteinIBA 11/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 11/2021
1	C-Reactive ProteinIBA 11/2021
1	ResistinIBA 10/2021
1	Interleukin-8 (Interleukin 8)IBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 10/2021
1	Ramipril (Altace)FDA LinkGeneric 05/2021
1	Lysine (L-Lysine)FDA Link 05/2021
1	VimentinIBA 05/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2021
1	2- ((4- methylphenyl)sulfonyl)- 5- nitrofuranIBA 05/2021
1	Peptides (Polypeptides)IBA 01/2021
1	NPHS2 proteinIBA 01/2021
1	Periodic AcidIBA 01/2021
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2021
1	nephrinIBA 01/2021
1	Tryptophan (L-Tryptophan)FDA Link 01/2020
1	C-PeptideIBA 01/2017
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2016
1	Forkhead Box Protein O1IBA 01/2016
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 09/2015

Therapy/Procedure

2	Therapeutics 12/2021 - 11/2021
1	Injections 01/2021
1	Ligation 10/2015